Author: macrophagepharma

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

10th September 2018, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today the formation of an international Scientific Advisory Board (SAB). The Scientific Advisory Board will closely work with management team as it … Continue reading “Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board”

Macrophage Pharma Appoints Dr Michael Moore as Chairman

11 April 2018, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today that it has appointed Dr. Michael Moore as non-executive Chairman with immediate effect. Commenting on the appointment, Steven Powell, CEO of … Continue reading “Macrophage Pharma Appoints Dr Michael Moore as Chairman”

Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference

7 November 2017, Windsor, UK: Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that two abstracts will be presented on its proprietary Esterase Sensitive Motif™ (ESM™) technology and its lead development candidate, MPL-5821, a macrophage targeted p38 MAP kinase inhibitor, at the … Continue reading “Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference”

Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures

Merck Ventures Joins Investment Syndicate and the Board of Macrophage Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that it has raised additional funding from Merck Ventures to complete the Series A Financing announced in January 2017.  Merck Ventures joins the existing … Continue reading “Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures”

Macrophage Pharma Appoints Development Director

Dr Joanne Bedwell-Garner joins management team Macrophage Pharma Limited (‘MPL’) the immuno-oncology development company, announced today that it has appointed Dr Joanne Bedwell-Garner as Development Director. Dr Bedwell-Garner will be responsible for advancing the clinical development of Macrophage Pharma’s lead programme, MPL-5821. This announcement follows the recent £9 million Series A financing, which was led … Continue reading “Macrophage Pharma Appoints Development Director”

Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform

Macrophage Pharma Limited, a newly formed immune-oncology company, today announced that it has successfully raised £9 million in a Series A equity financing round. The Company has also acquired global rights to a novel technology platform, Esterase Sensitive Motif (ESM), from Chroma Therapeutics Limited (Oxford, UK) together with discovery stage therapeutic assets. Macrophage Pharma was … Continue reading “Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform”